Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):e105-9. doi: 10.1016/j.clml.2013.12.013. Epub 2013 Dec 27.

Abstract

A 67-year-old male received an HLA matched unrelated peripheral blood stem cell transplant after a non-myeloablative conditioning regimen for heavily pretreated refractory chronic lymphocytic leukemia (CLL) in partial remission. His disease relapsed on day +90 post-transplant with persistent 100% engraftment of the donor cells. Immunusuppression was tapered off by day +96 and he was started on lenalidomide 10 mg per day on day +126. After 6 doses he acutely developed severe hepatitis potentially attributed to the lenalidomide mediated graft-versus-host disease. His liver enzymes slowly improved after cessation of lenalidomide and he achieved complete remission (CR) of the CLL without further treatment, presumably attributed to the graft-versus-leukemia effect induced by lenalidomide. He is alive and in CR over four years after the transplant with no additional therapy.

Keywords: GVHD; Hepatitis; Refractory CLL.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Bone Marrow / pathology
  • Graft vs Leukemia Effect / drug effects*
  • Graft vs Leukemia Effect / immunology*
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunologic Factors / pharmacology*
  • Lenalidomide
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy
  • Lymphatic Diseases / diagnosis
  • Lymphatic Diseases / etiology
  • Male
  • Positron-Emission Tomography
  • Recurrence
  • Thalidomide / analogs & derivatives*
  • Thalidomide / pharmacology
  • Tomography, X-Ray Computed
  • Transplantation, Homologous

Substances

  • Immunologic Factors
  • Thalidomide
  • Lenalidomide